Profile and outcome of treatment in non-small cell lung cancer with brain metastasis

Uzma Rehman; Nazir Ahmed Khan; Shahida Nasreen; Irfan Rasool Gadda

doi:10.18203/2320-6012.ijrms20241551

Authors

Uzma Rehman Department of Radiation Oncology, Sher ‑I‑ Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Nazir Ahmed Khan Department of Radiation Oncology, Sher ‑I‑ Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Shahida Nasreen Department of Radiation Oncology, Sher ‑I‑ Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Irfan Rasool Gadda Department of Radiation Oncology, Government Medical College, Srinagar, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241551

Keywords:

Lung carcinoma, Brain mets, WBRT

Abstract

Background: Brain metastasis is a common problem in patients with NSCLC. This study was done to study the risk factors associated with the development of brain metastasis and assess treatment response in NSCLC to improve patient survival.

Methods: This was a retro-prospective study in which 126 patients with non-small cell lung carcinoma with brain metastasis were taken for the study.

Results: The mean age in study group was 56.1±12.72 years. Adenocarcinoma was found in 57.1% and squamous cell carcinoma in 41.3% patients. 65.9% patients received chemotherapy for primary disease followed by targeted therapy in 34 (27.0%) patients. 53.9% patients received WBRT after diagnosis of brain metastasis and 23% WBRT and systemic chemotherapy while as14.3% received WBRT and targeted therapy and 2.4% received WBRT, systemic chemotherapy and targeted therapy, 1.6% patients received systemic chemotherapy, WBRT and local RT to the primary site and 0.8% each was treated with gamma knife therapy; surgery, WBRT and targeted therapy; SRS and WBRT. Median overall survival of patients with brain metastasis who received WBRT was 2.5 months and patients who received WBRT and systemic chemotherapy was 9.0 months while patients with brain metastasis who received WBRT and targeted therapy was 14.3 months.

Conclusions: The median overall survival as per treatment received after diagnosis of brain metastasis was higher in patients who received WBRT and targeted therapy as compared to patients who received WBRT and systemic chemotherapy and patients who received WBRT only.

Metrics

Metrics Loading ...

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, and Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organisation Classification of Lung Tumours: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thoracic Oncol. 2015;10:1243-60.

Truini A, Santos Pereira P, Cavazza A, Spagnolo P, Nosseir S, Longo, L, et al. Classification of Different Patterns of Pulmonary Adenocarcinomas. Expert Rev Respir Med. 2015;9:571-86.

Schuette W. Treatment of brain metastasis from lung cancer chemotherapy. Lung Cancer 2004;45(2):S253-7.

Louie AV, Rodrigues G, Yaremko B, Edward Y, Dar AR, Dingle B, et al. Management and prognosis in synchronous solitary resected brain metastasis from non-small cell lung cancer. Clin Lung Cancer. 2009;10(3):174-9.

Villano JL, Durbin EB, Normandeau C, Jigisha PT, Valentina M, Faith GD. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol 2015;17(1):122-8.

Smedby KE, Brandt L, Bäcklund M. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer. 2009;101(11):1919.

Mehta MP, Rodrigus P, Terhaard C, Aroor R, John S, Wilson R, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21(13):2529-36.

Ceresoli GL, Reni M, Chiesa G, Angelo C, Stefano S, Paolo P, et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer. 2002;95(3):605-12.

Mujoomdar A, Austin JH, Malhotra R, Charles AP, Gregory DNP, Maria CS, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumour size, cell type, and lymph node metastases. Radiology. 2007;242(3):882-8.

Wang SY, Ye X, Ou W, Yong-Bin L, Bin-Bin Z, Hua Y. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer. 2009;64(2):238-43.

Won YW, Joo J, Yun T, Geon-Kook L, Ji-Youn H, Heung TK, et al. A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. Lung Cancer. 2015;88(2):201-7.

Lee H, Jeong SH, Jeong BH, Hye YP, Kyung-JL, Sang-Won U, et al. Incidence of brain metastasis at the initial diagnosis of lung squamous cell carcinoma on the basis of stage, excluding brain metastasis. J Thorac Oncol. 2016;11(3):426-31.

Schuette W. Treatment of brain metastasis from lung cancer chemotherapy. Lung Cancer. 2004;45(2):S253-7.

Flannery TW, Suntharalingam M, Kwok Y, Bradley HK, Pradip PA, Lawrence SC, et al. Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer. 2003;42(3):327-33.

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500.

Greig NH. Chemotherapy of brain metastases: current status. Cancer Treat Rev. 1984;11:157-86.

Kelly K, Bunn Jr PA. Is it time to reevaluate our approach to the treatment of brain metastasis in patients with non-small cell lung cancer? Lung Cancer. 1998;20(2):85-91.

Horton J, Baxter DH, Olson DB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med. 1971;111:334-6.

Posner J. Management of central nervous system metastases. Sem Oncol. 1997;4:81-91.

Zabel A, Debus J. Treatment of brain metastases from non-small cell lung cancer: radiotherapy. Lung Cancer. 2004;45(2):247-252.

Mussi A, Pistolesi M, Lucchi M, Janni A, Chella A, Parrenti G, et al. Resection of single brain metastasis in non-small cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg 1996;112(1):146-53.

Granone P, Margarita S, Andrilli AD, Cesario A, Kawamura K, Meacci E. N0n-small cell lung cancer with single brain metastasis: the role of surgical treatment. Eur J Cardiothorac Surg. 2001;20(2):361-6.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:229-39.

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. AnnOncol. 2016;27(5):V1-27.

Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget. 2017;8:50209-20.

Antuna AR, Vega MA, Sanchez CR, Fernandez VM. Brain Metastases of Non-Small Cell Lung Cancer: Prognostic Factors in Patients with Surgical Resection. J Neurol Surg a Cent Eur Neurosurg. 2018;79(2):101-7.

Lee JS, Hong JH, Sun DS, Won HS, Kim YH. The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study. Scientific Rep. 2019;9:18689.

Chawla S, Tewarie IA, Zhang QO, Hulsbergen AFC, Mekary RA, Broekman MLD. The effect of smoking on survival in lung carcinoma patients with brain metastasis: a systematic review and meta-analysis. Neurosurg Rev. 2022;45(5):3055-66.

He J, Wang X, Xiao R, Zuo W, Zhang W, Yao H. Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study. Medicine (Baltimore). 2021;100(9):1.

Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277-83.

O'Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;(6):CD002140.

Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 2013;20(4):e300-6.

Chen XR, Hou X, Dinglin XX, Liu YD, Li Y, Zheng W, et al. Treatment patterns and survival outcomes of non-small cell lung cancer patients initially diagnosed with brain metastases in real-world clinical practice. Front Oncol. 2020;10:581729.